Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in Int J Oncol

Retrieve available abstracts of 74 articles:
HTML format
Text format



Single Articles


    June 2018
  1. LIU J, Liu D, Liu JJ, Zhao C, et al
    Blocking the Nav1.5 channel using eicosapentaenoic acid reduces migration and proliferation of ovarian cancer cells.
    Int J Oncol. 2018 Jun 12. doi: 10.3892/ijo.2018.4437.
    PubMed     Text format     Abstract available


    May 2018
  2. SONG J, Zhang W, Wang S, Liu K, et al
    A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer.
    Int J Oncol. 2018 May 11. doi: 10.3892/ijo.2018.4403.
    PubMed     Text format     Abstract available


    March 2018
  3. TANG G, Guo J, Zhu Y, Huang Z, et al
    Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation.
    Int J Oncol. 2018 Mar 29. doi: 10.3892/ijo.2018.4343.
    PubMed     Text format     Abstract available


    January 2018
  4. XU M, Xiao J, Chen M, Yuan L, et al
    miR1495p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway.
    Int J Oncol. 2018 Jan 24. doi: 10.3892/ijo.2018.4252.
    PubMed     Text format     Abstract available


    November 2017
  5. CHANG RK, Li X, Mu N, Hrydziuszko O, et al
    MicroRNA expression profiles in nonepithelial ovarian tumors.
    Int J Oncol. 2017 Nov 10. doi: 10.3892/ijo.2017.4200.
    PubMed     Text format     Abstract available


    October 2017
  6. SHETA R, Bachvarova M, Plante M, Gregoire J, et al
    Altered expression of different GalNActransferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
    Int J Oncol. 2017 Oct 9. doi: 10.3892/ijo.2017.4147.
    PubMed     Text format     Abstract available


  7. PAN H, Wang F, Rankin GO, Rojanasakul Y, et al
    Inhibitory effect of black tea pigments, theaflavin3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest.
    Int J Oncol. 2017 Oct 3. doi: 10.3892/ijo.2017.4145.
    PubMed     Text format     Abstract available


  8. GUO J, Cai J, Zhang Y, Zhu Y, et al
    Establishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: A comparative study.
    Int J Oncol. 2017;51:1199-1208.
    PubMed     Text format     Abstract available


    September 2017
  9. BU S, Zhang Q, Wang Q, Lai D, et al
    Human amniotic epithelial cells inhibit growth of epithelial ovarian cancer cells via TGFbeta1-mediated cell cycle arrest.
    Int J Oncol. 2017 Sep 14. doi: 10.3892/ijo.2017.4123.
    PubMed     Text format     Abstract available


    August 2017
  10. QIU JJ, Zhang XD, Tang XY, Zheng TT, et al
    ElncRNA1, a long non-coding RNA that is transcriptionally induced by oestrogen, promotes epithelial ovarian cancer cell proliferation.
    Int J Oncol. 2017;51:507-514.
    PubMed     Text format     Abstract available


    May 2017
  11. LI X, Jin Y, Mu Z, Chen W, et al
    MicroRNA146a5p enhances cisplatininduced apoptosis in ovarian cancer cells by targeting multiple antiapoptotic genes.
    Int J Oncol. 2017 May 29. doi: 10.3892/ijo.2017.4023.
    PubMed     Text format     Abstract available


  12. PALMA FLORES C, Garcia-Vazquez R, Gallardo Rincon D, Ruiz-Garcia E, et al
    MicroRNAs driving invasion and metastasis in ovarian cancer: Opportunities for translational medicine (Review).
    Int J Oncol. 2017;50:1461-1476.
    PubMed     Text format     Abstract available


  13. YANG J, Wang Y, Zeng Z, Qiao L, et al
    Smad4 deletion in blood vessel endothelial cells promotes ovarian cancer metastasis.
    Int J Oncol. 2017;50:1693-1700.
    PubMed     Text format     Abstract available


    April 2017
  14. XU J, Jiang N, Shi H, Zhao S, et al
    [Corrigendum] miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1.
    Int J Oncol. 2017 Apr 27. doi: 10.3892/ijo.2017.3977.
    PubMed     Text format     Abstract available


    March 2017
  15. DEVOR EJ, Gonzalez-Bosquet J, Warrier A, Reyes HD, et al
    p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers.
    Int J Oncol. 2017 Mar 23. doi: 10.3892/ijo.2017.3931.
    PubMed     Text format     Abstract available


  16. XU J, Jiang N, Shi H, Zhao S, et al
    miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1.
    Int J Oncol. 2017 Mar 16. doi: 10.3892/ijo.2017.3915.
    PubMed     Text format     Abstract available


  17. YOKOYAMA T, Kohn EC, Brill E, Lee JM, et al
    Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP.
    Int J Oncol. 2017 Mar 15. doi: 10.3892/ijo.2017.3914.
    PubMed     Text format     Abstract available


  18. CHA HJ, Choi JH, Park IC, Kim CH, et al
    Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells.
    Int J Oncol. 2017 Mar 15. doi: 10.3892/ijo.2017.3913.
    PubMed     Text format     Abstract available


  19. LI J, Li Q, Huang H, Li Y, et al
    Overexpression of miRNA-221 promotes cell proliferation by targeting the apoptotic protease activating factor-1 and indicates a poor prognosis in ovarian cancer.
    Int J Oncol. 2017 Mar 7. doi: 10.3892/ijo.2017.3898.
    PubMed     Text format     Abstract available


  20. WANG Y, Compton C, Rankin GO, Cutler SJ, et al
    3-Hydroxyterphenyllin, a natural fungal metabolite, induces apoptosis and S phase arrest in human ovarian carcinoma cells.
    Int J Oncol. 2017 Mar 2. doi: 10.3892/ijo.2017.3894.
    PubMed     Text format     Abstract available


    February 2017
  21. VERA CA, Orostica L, Gabler F, Ferreira A, et al
    The nerve growth factor alters calreticulin translocation from the endoplasmic reticulum to the cell surface and its signaling pathway in epithelial ovarian cancer cells.
    Int J Oncol. 2017 Feb 28. doi: 10.3892/ijo.2017.3892.
    PubMed     Text format     Abstract available


  22. SATO M, Kawana K, Adachi K, Fujimoto A, et al
    Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro.
    Int J Oncol. 2017 Feb 23. doi: 10.3892/ijo.2017.3891.
    PubMed     Text format     Abstract available


  23. PARK SH, Chung YJ, Song JY, Kim SI, et al
    Mullerian inhibiting substance inhibits an ovarian cancer cell line via beta-catenin interacting protein deregulation of the Wnt signal pathway.
    Int J Oncol. 2017 Feb 13. doi: 10.3892/ijo.2017.3874.
    PubMed     Text format     Abstract available


  24. ZHU X, Ji M, Han Y, Guo Y, et al
    PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment.
    Int J Oncol. 2017 Feb 10. doi: 10.3892/ijo.2017.3873.
    PubMed     Text format     Abstract available


    January 2017
  25. ZHOU G, Peng F, Zhong Y, Chen Y, et al
    Rhein suppresses matrix metalloproteinase production by regulating the Rac1/ROS/MAPK/AP-1 pathway in human ovarian carcinoma cells.
    Int J Oncol. 2017 Jan 17. doi: 10.3892/ijo.2017.3853.
    PubMed     Text format     Abstract available


    December 2016
  26. OTTE A, Yang Y, von der Ohe J, Melzer C, et al
    SCCOHT tumors acquire chemoresistance and protection by interacting mesenchymal stroma/stem cells within the tumor microenvironment.
    Int J Oncol. 2016;49:2453-2463.
    PubMed     Text format     Abstract available


    November 2016
  27. FU QR, Song W, Deng YT, Li HL, et al
    ESC-3 induces apoptosis of human ovarian carcinomas through Wnt/beta-catenin and Notch signaling in vitro and in vivo.
    Int J Oncol. 2016 Nov 18. doi: 10.3892/ijo.2016.3773.
    PubMed     Text format     Abstract available


  28. TURCONI G, Scaldaferri D, Fabbri M, Monti L, et al
    RNASET2 silencing affects miRNAs and target gene expression pattern in a human ovarian cancer cell model.
    Int J Oncol. 2016 Nov 9. doi: 10.3892/ijo.2016.3763.
    PubMed     Text format     Abstract available


    October 2016
  29. XIE Q, Su J, Jiao B, Shen L, et al
    ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells.
    Int J Oncol. 2016 Oct 13. doi: 10.3892/ijo.2016.3733.
    PubMed     Text format     Abstract available


    September 2016
  30. CHEN WC, Hsu HP, Li CY, Yang YJ, et al
    Cancer stem cell marker CD90 inhibits ovarian cancer formation via beta3 integrin.
    Int J Oncol. 2016 Sep 15. doi: 10.3892/ijo.2016.3691.
    PubMed     Text format     Abstract available


  31. LEE J, An S, Choi YM, Lee J, et al
    Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Int J Oncol. 2016 Sep 6. doi: 10.3892/ijo.2016.3683.
    PubMed     Text format     Abstract available


  32. PUVANENTHIRAN S, Essapen S, Seddon AM, Modjtahedi H, et al
    Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
    Int J Oncol. 2016 Sep 5. doi: 10.3892/ijo.2016.3678.
    PubMed     Text format     Abstract available


  33. MASUYAMA H, Nakamura K, Nobumoto E, Hiramatsu Y, et al
    Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells.
    Int J Oncol. 2016;49:1211-20.
    PubMed     Text format     Abstract available


    August 2016
  34. WU W, Wang Q, Yin F, Yang Z, et al
    Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer.
    Int J Oncol. 2016 Aug 10. doi: 10.3892/ijo.2016.3652.
    PubMed     Text format     Abstract available


    June 2016
  35. CHEN C, Chang YC, Lan MS, Breslin M, et al
    [Corrigendum] Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.
    Int J Oncol. 2016 Jun 6. doi: 10.3892/ijo.2016.3564.
    PubMed     Text format     Abstract available


  36. XIANG XY, Kang JS, Yang XC, Su J, et al
    SIRT3 participates in glucose metabolism interruption and apoptosis induced by BH3 mimetic S1 in ovarian cancer cells.
    Int J Oncol. 2016 Jun 1. doi: 10.3892/ijo.2016.3552.
    PubMed     Text format     Abstract available


  37. WANG D, Saga Y, Sato N, Nakamura T, et al
    The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway.
    Int J Oncol. 2016;48:2303-9.
    PubMed     Text format     Abstract available


    May 2016
  38. ROGERS-BROADWAY KR, Chudasama D, Pados G, Tsolakidis D, et al
    Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro.
    Int J Oncol. 2016 May 18. doi: 10.3892/ijo.2016.3531.
    PubMed     Text format     Abstract available


  39. QI X, Du L, Chen X, Chen L, et al
    VEGF-D-enhanced lymph node metastasis of ovarian cancer is reversed by vesicular stomatitis virus matrix protein.
    Int J Oncol. 2016 May 17. doi: 10.3892/ijo.2016.3527.
    PubMed     Text format     Abstract available


    April 2016
  40. HABATA S, Iwasaki M, Sugio A, Suzuki M, et al
    BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer.
    Int J Oncol. 2016 Apr 21. doi: 10.3892/ijo.2016.3494.
    PubMed     Text format     Abstract available


  41. TU Y, Kim E, Gao Y, Rankin GO, et al
    Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells.
    Int J Oncol. 2016 Apr 6. doi: 10.3892/ijo.2016.3472.
    PubMed     Text format     Abstract available


    March 2016
  42. LIU R, Martin TA, Jordan NJ, Ruge F, et al
    Epithelial protein lost in neoplasm-alpha (EPLIN-alpha) is a potential prognostic marker for the progression of epithelial ovarian cancer.
    Int J Oncol. 2016 Mar 29. doi: 10.3892/ijo.2016.3462.
    PubMed     Text format     Abstract available


  43. ZHOU B, Sun C, Li N, Shan W, et al
    Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways.
    Int J Oncol. 2016 Mar 15. doi: 10.3892/ijo.2016.3442.
    PubMed     Text format     Abstract available


  44. AGUILAR-ROJAS A, Perez-Solis MA, Maya-Nunez G
    The gonadotropin-releasing hormone system: Perspectives from reproduction to cancer (Review).
    Int J Oncol. 2016;48:861-8.
    PubMed     Text format     Abstract available


  45. MANKARIOUS A, Dave F, Pados G, Tsolakidis D, et al
    The pro-social neurohormone oxytocin reverses the actions of the stress hormone cortisol in human ovarian carcinoma cells in vitro.
    Int J Oncol. 2016 Mar 1. doi: 10.3892/ijo.2016.3410.
    PubMed     Text format     Abstract available


    February 2016
  46. ZHAO M, Wei C, Yang X, Zhou J, et al
    The milk-derived hexapeptide PGPIPN inhibits the invasion and migration of human ovarian cancer cells by regulating the expression of MTA1 and NM23H1 genes.
    Int J Oncol. 2016 Feb 12. doi: 10.3892/ijo.2016.3390.
    PubMed     Text format     Abstract available


  47. ANTONILLI M, Rahimi H, Visconti V, Napoletano C, et al
    Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.
    Int J Oncol. 2016 Feb 8. doi: 10.3892/ijo.2016.3386.
    PubMed     Text format     Abstract available


    January 2016
  48. LI L, Yu J, Duan Z, Dang HX, et al
    The effect of NFATc1 on vascular generation and the possible underlying mechanism in epithelial ovarian carcinoma.
    Int J Oncol. 2016 Jan 25. doi: 10.3892/ijo.2016.3355.
    PubMed     Text format     Abstract available


  49. SKIRNISDOTTIR I, Seidal T, Akerud H
    The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I-II.
    Int J Oncol. 2016 Jan 12. doi: 10.3892/ijo.2016.3333.
    PubMed     Text format     Abstract available


    November 2015
  50. NAKAYAMA K, Rahman MT, Rahman M, Nakamura K, et al
    CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
    Int J Oncol. 2015 Nov 26. doi: 10.3892/ijo.2015.3268.
    PubMed     Text format     Abstract available


  51. GAO Y, Rankin GO, Tu Y, Chen YC, et al
    Theaflavin-3, 3'-digallate decreases human ovarian carcinoma OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not via MAPK pathways.
    Int J Oncol. 2015 Nov 20. doi: 10.3892/ijo.2015.3257.
    PubMed     Text format     Abstract available


  52. LIU X, Zou J, Su J, Lu Y, et al
    Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.
    Int J Oncol. 2015 Nov 19. doi: 10.3892/ijo.2015.3254.
    PubMed     Text format     Abstract available


  53. TAN H, He Q, Gong G, Wang Y, et al
    miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer.
    Int J Oncol. 2015 Nov 9. doi: 10.3892/ijo.2015.3241.
    PubMed     Text format     Abstract available


  54. DENG Z, Wang L, Hou H, Zhou J, et al
    Epigenetic regulation of IQGAP2 promotes ovarian cancer progression via activating Wnt/beta-catenin signaling.
    Int J Oncol. 2015 Nov 4. doi: 10.3892/ijo.2015.3228.
    PubMed     Text format     Abstract available


    October 2015
  55. MIURA R, Yokoyama Y, Shigeto T, Futagami M, et al
    Inhibitory effect of carbonyl reductase 1 on ovarian cancer growth via tumor necrosis factor receptor signaling.
    Int J Oncol. 2015 Oct 13. doi: 10.3892/ijo.2015.3205.
    PubMed     Text format     Abstract available


  56. WAN J, Shi F, Xu Z, Zhao M, et al
    Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells.
    Int J Oncol. 2015 Oct 13. doi: 10.3892/ijo.2015.3201.
    PubMed     Text format     Abstract available


  57. TAKAHASHI Y, Saga Y, Koyanagi T, Takei Y, et al
    The angiogenesis regulator vasohibin-1 inhibits ovarian cancer growth and peritoneal dissemination and prolongs host survival.
    Int J Oncol. 2015 Oct 8. doi: 10.3892/ijo.2015.3193.
    PubMed     Text format     Abstract available


  58. KATAGIRI H, Nakayama K, Razia S, Nakamura K, et al
    Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas.
    Int J Oncol. 2015 Oct 6. doi: 10.3892/ijo.2015.3191.
    PubMed     Text format     Abstract available


    September 2015
  59. MA L, Xu Y, Su J, Yu H, et al
    Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function.
    Int J Oncol. 2015 Sep 21. doi: 10.3892/ijo.2015.3176.
    PubMed     Text format     Abstract available


    August 2015
  60. LIU R, Martin TA, Jordan NJ, Ruge F, et al
    Metastasis suppressor 1 expression in human ovarian cancer: The impact on cellular migration and metastasis.
    Int J Oncol. 2015 Aug 13. doi: 10.3892/ijo.2015.3121.
    PubMed     Text format     Abstract available


  61. SO KA, Min KJ, Hong JH, Lee JK, et al
    Interleukin-6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelial-mesenchymal transition.
    Int J Oncol. 2015 Aug 13. doi: 10.3892/ijo.2015.3122.
    PubMed     Text format     Abstract available


  62. JI F, Chang X, Liu C, Meng L, et al
    Prognostic value and characterization of the ovarian cancer-specific antigen CA166-9.
    Int J Oncol. 2015 Aug 6. doi: 10.3892/ijo.2015.3115.
    PubMed     Text format     Abstract available


    July 2015
  63. LI Z, Sun L, Lu Z, Su X, et al
    Enhanced effect of photodynamic therapy in ovarian cancer using a nanoparticle drug delivery system.
    Int J Oncol. 2015 Jul 10. doi: 10.3892/ijo.2015.3079.
    PubMed     Text format     Abstract available


  64. YANG Y, Bucan V, Baehre H, von der Ohe J, et al
    Acquisition of new tumor cell properties by MSC-derived exosomes.
    Int J Oncol. 2015;47:244-52.
    PubMed     Text format     Abstract available


    May 2015
  65. KIM NY, Lee HY, Lee C
    Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
    Int J Oncol. 2015 May 12. doi: 10.3892/ijo.2015.3004.
    PubMed     Text format     Abstract available


  66. PASTOREK M, Simko V, Takacova M, Barathova M, et al
    Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy.
    Int J Oncol. 2015 May 5. doi: 10.3892/ijo.2015.2987.
    PubMed     Text format     Abstract available


    April 2015
  67. CHEN J, Chen AY, Huang H, Ye X, et al
    The flavonoid nobiletin inhibits tumor growth and angiogenesis of ovarian cancers via the Akt pathway.
    Int J Oncol. 2015 Apr 1. doi: 10.3892/ijo.2015.2946.
    PubMed     Text format     Abstract available


    March 2015
  68. WEN C, Liu X, Ma H, Zhang W, et al
    miR3383p suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2.
    Int J Oncol. 2015 Mar 16. doi: 10.3892/ijo.2015.2929.
    PubMed     Text format     Abstract available


    February 2015
  69. SU M, Chang W, Cui M, Lin Y, et al
    Expression and anticancer activity analysis of recombinant human uPA143-melittin.
    Int J Oncol. 2015;46:619-26.
    PubMed     Text format     Abstract available


    January 2015
  70. TAKAYA A, Peng WX, Ishino K, Kudo M, et al
    Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.
    Int J Oncol. 2015 Jan 28. doi: 10.3892/ijo.2015.2858.
    PubMed     Text format     Abstract available


    November 2014
  71. SAYASNEH A, Ekechi C, Ferrara L, Kaijser J, et al
    The characteristic ultrasound features of specific types of ovarian pathology (Review).
    Int J Oncol. 2014 Nov 18. doi: 10.3892/ijo.2014.2764.
    PubMed     Text format     Abstract available


  72. BRACHOVA P, Mueting SR, Carlson MJ, Goodheart MJ, et al
    TP53 oncomorphic mutations predict resistance to platinum and taxanebased standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Int J Oncol. 2014 Nov 11. doi: 10.3892/ijo.2014.2747.
    PubMed     Text format     Abstract available


    October 2014
  73. SUN Q, Yogosawa S, Iizumi Y, Sakai T, et al
    The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL.
    Int J Oncol. 2014 Oct 8. doi: 10.3892/ijo.2014.2703.
    PubMed     Text format     Abstract available


  74. YI BR, Kim TH, Kim YS, Choi KC, et al
    Alteration of epithelial-mesenchymal transition markers in human normal ovaries and neoplastic ovarian cancers.
    Int J Oncol. 2014 Oct 7. doi: 10.3892/ijo.2014.2695.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: